Citadel Advisors
NMTC icon

Citadel Advisors’s NeuroOne Medical Technologies NMTC Stock Holding History

Citadel Advisors’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.8K Sell
16,917
-416
-2% -$2K ﹤0.01% 12183
2025
Q4 		$78.8K Buy
17,333
+13,750
+384% +$62.6K ﹤0.01% 11805
2025
Q3 		$19.1K Sell
3,583
-17,267
-83% -$84.5K ﹤0.01% 12496
2025
Q2 		$84.9K Buy
20,850
+9,250
+80% +$34.2K ﹤0.01% 11448
2025
Q1 		$59.2K Buy
11,600
+4,800
+71% +$30.5K ﹤0.01% 12131
2024
Q4 		$33.7K Buy
+6,800
New +$33.9K ﹤0.01% 12764
2024
Q1 		– Sell
-2,467
Closed -$23.4K – 15200
2023
Q4 		$23.4K Buy
2,467
+484
+24% +$3.57K ﹤0.01% 12492
2023
Q3 		$10.6K Buy
+1,983
New +$13.3K ﹤0.01% 13052
2023
Q1 		– Sell
-1,217
Closed -$8.76K – 15222
2022
Q4 		$8.76K Buy
+1,217
New +$10.9K ﹤0.01% 13733

Other funds holding NMTC

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Citadel Advisors's NMTC Position: Q1 2026 in Review

Citadel Advisors sold out of NeuroOne Medical Technologies (NMTC) in Q1 2026, closing a stake of 7,382 shares — an estimated $35.5K sold.

Citadel Advisors first reported a position in NMTC in Q4 2022 and held it in 6 quarters. The position peaked at $183K in Q3 2025. 32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

  • Citadel Advisors reported no remaining NeuroOne Medical Technologies position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 7,382 NeuroOne Medical Technologies shares in Q1 2026, an estimated $35.5K.
  • Citadel Advisors first reported a position in NeuroOne Medical Technologies in Q4 2022 and held it in 6 quarters.
  • Citadel Advisors's NeuroOne Medical Technologies position peaked at $183K in Q3 2025.
  • 32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.